- Популярные видео
- Авто
- Видео-блоги
- ДТП, аварии
- Для маленьких
- Еда, напитки
- Животные
- Закон и право
- Знаменитости
- Игры
- Искусство
- Комедии
- Красота, мода
- Кулинария, рецепты
- Люди
- Мото
- Музыка
- Мультфильмы
- Наука, технологии
- Новости
- Образование
- Политика
- Праздники
- Приколы
- Природа
- Происшествия
- Путешествия
- Развлечения
- Ржач
- Семья
- Сериалы
- Спорт
- Стиль жизни
- ТВ передачи
- Танцы
- Технологии
- Товары
- Ужасы
- Фильмы
- Шоу-бизнес
- Юмор
Starpharma (ASX:SPL, US OTC:SPHRY:SPL): Advancing dendrimer tech through partnerships & innovation
Starpharma (ASX:SPL, US OTC:SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. The company’s mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of its unique dendrimer platform technology. Starpharma Chief Executive Officer, Cheryl Maley, joins Lel Smits from The Stock Network.
1. Quarterly highlights: Major partnership wins
This quarter was a milestone period for Starpharma, securing two major global partnerships with Genentech and Radiopharm Theranostics, demonstrating growing industry validation and commercial traction for Starpharma’s DEP® platform. How do these achievements position Starpharma for its next phase of growth?
2. Strategic partnerships and commercial momentum
With Genentech providing access to world-leading oncology expertise and Radiopharm expanding into radiopharmaceuticals, Starpharma’s DEP® platform has gained powerful industry endorsement. How do these collaborations highlight the commercial power of the DEP® platform and what are your plans to maintain momentum?
3. Upcoming catalysts and FY26 focus
Looking ahead, what key milestones and development programs will drive Starpharma’s growth and value creation through FY26?
_ _ _
Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1
_ _ _
Follow TSN for the latest stock news and interviews:
Twitter: https://twitter.com/thestocknet
Instagram: https://www.instagram.com/thestocknetwork/
LinkedIn: https://www.linkedin.com/company/the-stock-network/
TikTok: https://www.tiktok.com/@thestocknet?lang=en
Facebook: https://www.facebook.com/TheStockNet/
_ _ _
Connect with our host Lel Smits online - @LelSmits
- Twitter / X: https://twitter.com/lelsmits
- Instagram: https://www.instagram.com/lelsmits/
- LinkedIn: https://www.linkedin.com/in/leldesmits/
- TikTok: https://www.tiktok.com/@lelsmits?lang=en
- Facebook: https://m.facebook.com/lelsmits/
- Threads: https://www.threads.net/@lelsmits
_ _ _
Disclaimer
The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss.
This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer.
_ _ _
Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au
_ _ _
Видео Starpharma (ASX:SPL, US OTC:SPHRY:SPL): Advancing dendrimer tech through partnerships & innovation канала The Stock Network
1. Quarterly highlights: Major partnership wins
This quarter was a milestone period for Starpharma, securing two major global partnerships with Genentech and Radiopharm Theranostics, demonstrating growing industry validation and commercial traction for Starpharma’s DEP® platform. How do these achievements position Starpharma for its next phase of growth?
2. Strategic partnerships and commercial momentum
With Genentech providing access to world-leading oncology expertise and Radiopharm expanding into radiopharmaceuticals, Starpharma’s DEP® platform has gained powerful industry endorsement. How do these collaborations highlight the commercial power of the DEP® platform and what are your plans to maintain momentum?
3. Upcoming catalysts and FY26 focus
Looking ahead, what key milestones and development programs will drive Starpharma’s growth and value creation through FY26?
_ _ _
Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1
_ _ _
Follow TSN for the latest stock news and interviews:
Twitter: https://twitter.com/thestocknet
Instagram: https://www.instagram.com/thestocknetwork/
LinkedIn: https://www.linkedin.com/company/the-stock-network/
TikTok: https://www.tiktok.com/@thestocknet?lang=en
Facebook: https://www.facebook.com/TheStockNet/
_ _ _
Connect with our host Lel Smits online - @LelSmits
- Twitter / X: https://twitter.com/lelsmits
- Instagram: https://www.instagram.com/lelsmits/
- LinkedIn: https://www.linkedin.com/in/leldesmits/
- TikTok: https://www.tiktok.com/@lelsmits?lang=en
- Facebook: https://m.facebook.com/lelsmits/
- Threads: https://www.threads.net/@lelsmits
_ _ _
Disclaimer
The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss.
This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer.
_ _ _
Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au
_ _ _
Видео Starpharma (ASX:SPL, US OTC:SPHRY:SPL): Advancing dendrimer tech through partnerships & innovation канала The Stock Network
Комментарии отсутствуют
Информация о видео
30 октября 2025 г. 3:47:44
00:04:32
Другие видео канала





















